EMEA issues guidelines on Alzheimer's and Parkinson's trials
This article was originally published in Scrip
New European guidelines which set out how disease modification might be demonstrated for experimental medicines for Alzheimer's disease and Parkinson's disease have been issued by the European Medicines Agency (EMEA).
You may also be interested in...
Amgen's investigational bone loss treatment denosumab more than halves osteoporosis patients' risk of new vertebral fractures, new data from a pivotal Phase III trial show.
Gilead Scienceswill need to conduct another clinical trial of its investigational cystic fibrosis treatment aztreonam lysine for inhalation before the drug can be approved, the US FDAhas said.